Casper is a 25 year veteran of the medical device and life sciences industry. He brings extensive operating experience to NVP having led marketing and commercialization efforts for cardiovascular device, specialty pharmaceutical and diagnostic companies. Based in NVP's Palo Alto office, Casper focuses on mid to late stage investments in medical devices, specialty pharmaceuticals and healthcare services. Therapeutic products that address a critical unmet medical need, that are “less” traumatic or have a defined path to regulatory approval are of particular interest. His current investments include Intersect ENT, iRhythm Technologies, Misfit Wearables and Simpirica Spine. Casper was previously on the board of Basis (acquired by Intel).
Prior to NVP, Casper was a Partner at U.S. Venture Partners (USVP) in Menlo Park, where he invested in therapeutic companies from clinical development through commercialization. At USVP, Casper served as a Board member for AtheroMed, Ilypsa (acquired by Amgen) and Valeritas. Over a six year period he was actively involved in making and managing investments in more than a dozen companies as a member of the healthcare team. Casper was also a private investor and board member with Innospine, an orthopedic diagnostic company acquired by Kyphon in 2005.
Previously, Casper spent four years as Vice President of Business Development, Sales and Marketing at Aerogen, a specialty pharmaceutical company developing inhaled therapeutics for diabetes and respiratory diseases (public company acquired by Nektar then Novartis). In 1999 he co-founded and venture funded Epicor to develop a market leading epicardial ablation treatment for atrial fibrillation (acquired by St. Jude Medical for over $200M in 2004).
Prior to Epicor, Casper held senior marketing positions at Heartport (acquired by Johnson and Johnson) and Diagnostic Products Corporation (acquired by Siemens). At Heartport, Casper launched an integrated surgical product line to perform minimally invasive cardiovascular surgery. Previously at Diagnostics Products Corporation, he managed a portfolio of oncology, infectious disease and infertility immunoassay tests which doubled to $105M in revenues during his tenure. At these companies, Casper worked closely with the engineering, scientific and clinical teams in product development, coordinated multiple U.S. product launches and had ongoing responsibility for managing international distribution.
Earlier in his career, Casper worked internationally for three years as a strategy consultant for Bain & Company.
Casper holds an M.B.A. from Stanford University Graduate School of Business, an M.S. in biological science from Stanford University and a B.A. in biochemistry from Dartmouth College.